MNPR
Monopar Therapeutics Inc
NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY
$52.15
+4.05% today
Updated 2026-04-30
Market cap
$361.51M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$28 – $105
Volume
0.2M
Monopar Therapeutics Inc (MNPR) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.83M | $2.90M | $9.93M | $7.32M | $13.35M | $16.87M | $20.52M | $13.23M | $7.35M | $60.29M |
| Cash & equivalents | $2.01M | $2.07M | $8.98M | $6.89M | $13.21M | $16.74M | $20.30M | $8.19M | $7.27M | $45.82M |
| Current assets | $2.03M | $2.10M | $9.13M | $7.32M | $13.23M | $16.80M | $20.52M | $13.17M | $7.33M | $60.29M |
| Total liabilities | $73843.00 | $64510.00 | $311867.00 | $399551.00 | $724165.00 | $1.18M | $1.58M | $3.14M | $1.76M | $5.25M |
| Current liabilities | $73843.00 | $64510.00 | $311867.00 | $399551.00 | $724165.00 | $1.18M | $1.58M | $3.13M | $1.76M | $5.25M |
| Long-term debt | — | — | — | — | — | — | — | — | — | — |
| Shareholder equity | $2.75M | $2.83M | $9.62M | $6.92M | $12.63M | $15.69M | $18.94M | $10.09M | $5.59M | $55.04M |
| Retained earnings | $-687311.00 | $-1.87M | $-18.43M | $-21.66M | $-25.88M | $-32.19M | $-41.29M | $-51.80M | $-60.21M | $-75.79M |
| Accounts receivable | — | — | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |